Thank you.
>I am looking for treatment information for Malignant Fibrous Histiocytoma.
>
Malignant Fibrous Histiocytoma is a rare disease, but Dr. Thomas Tallberg
has successfully treated at least a couple of cases here in Finland with his
active specific immunotherapy which consists of an autologous vaccine and
nutritional supplements. In one of the cases the lab was closed for
vacations, and the therapy was started without the vaccine, with nutritional
supplement only. Still, to everyone' surprise the tumor disappeared.
Dr. Tallberg is semi-retired and does not take new patients, but you could
inquire about supplements from his clinic, the contact info is
Voice: +358 9 700 39 340 (Tue-Thu, 9:30-16:00 Finnish time)
Fax: +358 9 674 117
See also
Complete disappearance of human malignant histiocytoma cells following
dietary biotherapy, leading to activation of inductional control mediated by
mitochondria.
Thomas Tallberg MD a, H. Stenbäck MS b, J. Dabek MD c and A. Palkama MD b
http://www.acnem.org/journal/15-2_december_1996/dietary_biotherapy_for_histiocytoma.htm
Cancer treatment, based on active nutritional biomodulation, hormonal
therapy and specific autologous immunotherapy.
Thomas Tallberg M.D Helsinki University Central Hospital
http://www.acnem.org/journal/15-1_april_1996/cancer_treatment_and_autologous_immunotherapy.htm
Biological Cancer Therapy, Its effect on inductional control, triggered by
hormones and mediated by transformed mitochondria.
Thomas Tallberg Dr Med Lecturer in Immunology - Helsinki University
http://www.acnem.org/journal/17-1_june_1998/biological_cancer_therapy.htm
Thomas Tallberg Cancer STP
June 1999
http://www.acnem.org/books/tapes_and_notes/cancer_tallberg_june-1999.htm
Lectures by Dr. Thomas Tallberg on
Cancer Bio-Immunotherapy and the Role of
Autologous Tumour Vaccines
http://www.kcuk.org/Events.htm#LECTURES%20BY%20DR.%20THOMAS%20TALLBERG%20ON%20CANCER%20%20%20BIO-IMMUNOTHERAPY%20AND%20THE%20ROLE%20OF%20%20%20AUTOLOGOUS%20TUMOUR%20VACCINES
in
http://www.kcuk.org/Events.htm
Medline references:
Tallberg T, Uusitalo R, Sarna S, Seregard S, Werschnik C.
Improvement of the recurrence-free interval using biological adjuvant
therapy in uveal melanoma.
Anticancer Res. 2000 May-Jun;20(3B):1969-75.
PMID: 10928136 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10928136&dopt=Abstract
Kinnunen RE, Tallberg T, Stenback H, Sarna S.
Equine sarcoid tumour treated by autogenous tumour vaccine.
Anticancer Res. 1999 Jul-Aug;19(4C):3367-74.
PMID: 10629622 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10629622&dopt=Abstract
Tallberg T, Kalima T, Halttunen P, Tykka H, Mahlberg K, Matous B, Sundell B.
Postoperative active specific immunotherapy with supportive measures in
patients suffering from recurrent metastasized melanoma: case reports of six
patients.
J Surg Oncol. 1986 Oct;33(2):115-9.
PMID: 3762183 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3762183&dopt=Abstract
Tallberg T, Tykka H, Mahlberg K, Halttunen P, Lehtonen T, Kalima T, Sarna S.
Active specific immunotherapy with supportive measures in the treatment of
palliatively nephrectomized, renal adenocarcinoma patients. A thirteen-year
follow-up study.
Eur Urol. 1985;11(4):233-43.
PMID: 2412827 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2412827&dopt=Abstract
Tykka H.
Active specific immunotherapy with supportive measures in the treatment of
advanced palliatively nephrectomised renal adenocarcinoma. A controlled
clinical study.
Scand J Urol Nephrol Suppl. 1981;63:1-107. No abstract available.
PMID: 6184775 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6184775&dopt=Abstract
Tykka H, Oravisto KJ, Lehtonen T, Sarna S, Tallberg T.
Active specific immunotherapy of advanced renal-cell carcinoma.
Eur Urol. 1978;4(4):250-8.
PMID: 668735 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=668735&dopt=Abstract
Tykka H, Hjelt L, Oravisto KJ, Turunen M, Tallberg T.
Disappearance of lung metastases during immunotherapy in five patients
suffering from renal carcinoma.
Scand J Respir Dis Suppl. 1974;89:123-34. No abstract available.
PMID: 4528514 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4528514&dopt=Abstract
--
Matti Narkia
>I am looking for treatment information for Malignant Fibrous Histiocytoma.
>
>Thank you.
That depends on location and stage mainly.
Age, other diseases, etc...
>Malignant Fibrous Histiocytoma is a rare disease, but Dr. Thomas Tallberg
>has successfully treated at least a couple of cases here in Finland with his
>active specific immunotherapy which consists of an autologous vaccine and
>nutritional supplements.
I have cured not a couple but many dozens with chemo and surgery.
And many doctors worldwide have also.
I'm glad to hear that you can do something other than to recommend people to
give up. I hope you'd tell us more about these positive activities.
--
Matti Narkia
Best treatment is surgical resection if possible, and radiotherapy if not
"You" don't do surgery.
And chemotherapy has never cured an MFH on its own.
MFH of bone has a tumor biology and treatment response very similar to
Osteosarcoma. As so primary treatment is chemo followed by surgery and
more chemo dependant on tumor necrosis. Very radioresistant.
MFH of soft tissues is slightly different, but primary chemo is the
best in my experience (quite large btw), followed by surgery and
radio.
Glad to see you back dear friend!
I kind of know that, but my wife who has been diagnosed with MALIGNANT
FIBROUS HISTIOCYTOMA OF PLEOMORPHIC TYPE in the posterior mediastinum
(High grade aggressive sarcoma) with tumor weight 900gr (2lb!!) has
evidence on new tumor i.e. reoccurrence adjacent to the thoracotomy
site and another two soft tissue adjacent to descending aorta (btw she
had a piece (8cm) of her aorta dissected too).
It's going to be difficult to operate on and on. These thing keeps
comming back. Also radiation is questionable due to proximity of other
vital organs (heart, lungs, etc).
So, what are other options in cases like this? Chemo does not work.
Continue with surgeries i.e. thoracotomies?
Nikola
In the meanwhile you can take a look whether the work the NIH is showing with
the use of chelators / iron 'binders' in the treatment of cancer may pertain to
your situation ?
http://www.koolpages.com/ironjustice/cancerpost.html
Who loves ya.
Tom
Jesus was a vegetarian! http://www.koolpages.com/ironjustice
Jesus was a vegetarian! http://www.nucleus.com/watchman
Moses was a mystic! http://www.nucleus.com/watchman/light.html
It seems 'rust' .. IS .. involved.
Therefore I would look into the effects of the low iron diet and the inclusion
of the phytic acid / IP6 in your research .. off my page.
--------------------------------------------------------
Rev Chir Orthop Reparatrice Appar Mot 2001 Feb 1;87(1):84-90 Related Articles,
Links
[Malignant fibrous histiocytoma of bone 20 years after femoral fracture treated
by plate-screw fixation: analysis of corrosion products and their role in
malignancy]
[Article in French]
Laffargue P, Hildebrand HF, Lecomte-Houcke M, Biehl V, Breme J, Decoulx J.
Clinique d'Orthopedie et de Traumatologie, Hopital Roger-Salengro, CHRU, 59037
Lille Cedex.
We report a case of malignant fibrous histiocytoma of the bone that developed
20 years after a femoral fracture treated by plate-screw fixation. Similar
cases reported over the past fifteen years in the literature suggest the
possible mechanisms of sarcomatous degeneration. The possible carcinogenic
effect of corrosion products is emphasized. Dispersion energy spectrometry of
intracellular particles on the periphery and at the center of the tumor
demonstrated the presence of chromium, iron and nickel at different
concentrations. The association with other elements clearly demonstrates that
the corrosion products were metabolized. The presence of metallic components in
tumoral cells suggests a possible relationship between metallic implants and
malignancy. These observations emphasize the importance of creating a national,
or even international, registry of malignant tumors that develop in contact
with metallic implants in order to search for a possible cause and effect
relationship.
Publication Types:
Review
Review of Reported Cases
PMID: 11240542 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------------------
------
>I kind of know that, but my wife who has been diagnosed with MALIGNANT
>FIBROUS HISTIOCYTOMA OF PLEOMORPHIC TYPE
Yep I would look into the iron and how it causes malignant fibrous
histiocytoma ..
--------------------------------------------------------
: Clin Nucl Med 1988 Oct;13(10):734-5 Related Articles, Links
Tc-99m diphosphonate uptake in malignant fibrous histiocytoma: a possible
iron-related effect.
Spencer RP, Evans DD, Forouhar F, Fetters DV, Yeh SD.
Department of Nuclear Medicine, University of Connecticut Health Center,
Farmington 06032.
A man with malignant fibrous histiocytoma of the thigh had avid uptake of
Tc-99m MDP in the lesion. Review of tissue sections showed considerable
accumulation of iron in the tumor. Iron is known to be a potential nidus for
deposition of the Tc-99m diphosphonates. A review was made of tissue sections
from two other reported cases of malignant fibrous histiocytoma which also had
significant accumulation of Tc-99m diphosphonates. Both revealed iron within
the tumor. The origin of the iron is unknown (perhaps from necrosis and
hemorrhage, from trauma, or from innate phagocytic activity of the
histiocytes). However, this observation may serve as a stimulus to studies
attempting to discern the underlying mechanisms of extraosseous deposition of
the Tc-99m diphosphonates.
PMID: 2846223 [PubMed - indexed for MEDLINE]
Radiation is the best option to explore. Local organs may limit dose and
volume, but are unlikely to prevent radiotherapy.